Intrauterine exposure to mycophenolate mofetil and multiple congenital anomalies in a newborn: Possible teratogenic effect

American Journal of Medical Genetics, Part A

Volumn 149, Issue 6, 2009, Pages 1231-1236

  Jackson, Paige ^a,c   Paquette, Lisa ^a   Watiker, Valerie ^b   Randolph, Linda ^b   Ramanathan, Rangasamy ^a   Seri, Istvan ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Cleft lip palate; Double outlet right ventricle; Microtia anotia; Multiple congenital anomalies; Mycophenolate mofetil; Teratogenicity

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CATARACT; CLEFT LIP; CLEFT PALATE; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; DRUG EXPOSURE; FEMALE; HUMAN; HYPERTELORISM; INFECTION PREVENTION; INTESTINE MALROTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MICROGNATHIA; MICROPHTHALMIA; MICROTIA; NEWBORN; NEWBORN DISEASE; PREMATURE LABOR; PRIORITY JOURNAL; RIB MALFORMATION; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; MYCOPHENOLIC ACID; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 66349123006     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32715     Document Type: Article

References (20)

1. Andrade Vila JH, Da Silva JP, Guilhen CJ, Baumgratz JF, Da Fonseca L. 2008. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation 86:369-370.
2. Ang GS, Simpson SA, Reddy AR. 2008. Mycophenolate mofetil embryopathy may be dose and timing dependent. Am J Med Genet Part A 146A:1963-1966.
3. Armenti VT, Radomski JS, Moritz MJ, Branch KR, McGrory CH, Coscia LA. 1999. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transpl 111-119.
4. Carey JC. 2008. Where observation is concerned, chance favors only the prepared mind. Obstet Gynecol 111:479-480.
5. El Sebaaly Z, Charpentier B, Snanoudj R. 2007. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 22:2722. (Pubitemid 47365542)
6. European Mycophenolate Mofetil Cooperative Study Group. 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325.
7. Guven MA, Batukan C, Ceylaner S, Ceylaner G, Uzel M. 2006. A case of fetal anticonvulsant syndrome with severe bilateral upper limb defect. J Matern Fetal Neonatal Med 19:115-117.
8. Holmes L, Harvey E, Coull BA, Huntington KB, Hoshbin SK, Hayes AM, Ryan LM. 2001. Teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132-1138. (Pubitemid 32285234)
9. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. 2004. Mycophenolate mofetil on pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol 103:1091-1094.
10. Loureiro K, Kao K, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. 2005. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet Part A 136A:117-121. (Pubitemid 40967099)
11. Organ Procurement and Transplantation Network. Scientific Registry of Transplant Recipients. The 2006 Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients Annual Report. Available at http://www.optn.org/data/annualReport.asp. Retrieved April 5, 2008.
12. Perez-Aytes A, Ledo A, Boso V, Saénz P, Roma E, Poveda JL, Vento M. 2008. In utero exposure to mycophenolate mofetil:Acharacteristic phenotype? Am J Med Genet Part A 146A:1-7.
13. Pergola P, Kancharla A, Riley D. 2001. Kidney transplantation during the first trimester of pregnancy: Immunosupression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 71:994-997. (Pubitemid 32417365)
14. Schoner K, Steinhard J, Figiel J, Rehder H. 2008. Severe facial clefts in acrofacial dysostosis: A consequence of prenatal exposure to mycophenolate mofetil? Obstet Gynecol 111:483-486.
15. Sifontis N, Coscia L, Constantinescu L, Lavelanet AF, Moritz MJ, Armenti VT. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698-1702. (Pubitemid 46035654)
16. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. 1995. Mycophenolate mofetil for the prevention of acute rejection in primary renal allograft recipients. Transplantation 60:225-232.
17. Tjeertes IF, Bastiaans DET, van Ganzewinkel CJLM, Zegers SHJ. 2007. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol 27:62-64. (Pubitemid 44971056)
18. US Food and Drug Administration. 2007 Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). Available at http://www.fda.gov/ medwatch. Last updated April 10, 2008.
19. Velinov M, Zellers N. 2008. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol 17:77-78.
20. Vento M, Perez-Aytes A, Ledo A, Boso V, Carey JC. 2008. Mycophenolate mofetil during pregnancy: Some words of caution. Pediatrics 122:184-185.